A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag

Journal of Immunology

Volumn 170, Issue 3, 2003, Pages 1416-1422

  Fitzgerald, Julie C ^a   Gao, Guang Ping ^b   Reyes Sandoval, Arturo ^a,d   Pavlakis, George N ^c   Xiang, Zhi Q ^a   Wlazlo, Anthony P ^a   Giles Davis, Wynetta ^a   Wilson, James M ^b   Ertl, Hildegund C J ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CELL SURFACE MARKER; DRUG CARRIER; GAG PROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL SELECTION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRUS RECOMBINATION;

EID: 0037310512     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.3.1416     Document Type: Article

References (27)

1. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Hemdon, L. S. Wyatt, et al. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69.
2. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Bilska. A. Craiu, X. X. Zheng, G. R. Krivulka, et al. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486.
3. Clerici, M., A. Salvi, D. Trabattoni, S. Lo Caputo, F. Semplici, M. Biasin, C. Ble, F. Meacci, C. Romeo, S. Piconi, et al. 1999. A role for mucosal immunity in resistance to HIV infection, Immunol. Lett. 66:21.
4. Egan, M. A., W. A. Charini, M. J. Kuroda, J. E. Schmitz, P. Racz, K. Tenner-Racz, K. Manson, M. Wyand, M. A. Lifton, C. E. Nickerson, et al. 2000. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J. Virol. 74:7485.
5. Rowland-Jones, S. L., and A. McMichael. 1995. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr. Opin. Immunol. 7:448.
6. He, Z., A. P. Wlazlo, D. W. Kowalczyk, J. Cheng, Z. Q. Xiang, W. Giles-Davis, and H. C. Ertl. 2000. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 270:146.
7. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605.
8. Xiang, Z. Q., Y. Yang, J. M. Wilson, and H. C. Ertl. 1996. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219:220.
9. Shiver, J. W., T. M. Fu. L. Chen, D. R. Casimiro. M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331.
10. Piedra, P. A., G. A. Poveda, B. Ramsey, K. McCoy, and P. W. Hiatt. 1998. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 101:1013.
11. Basnight, M., Jr., N. G. Rogers, C. J. Gibbs, Jr., and D. C. Gajdusek. 1971. Characterization of four new adenovirus serotypes isolated from chimpanzee tissue explants. Am. J. Epidemiol. 94:166.
12. Farina, S. F., G. P. Gao, Z. Q. Xiang, J. J. Rux, R. M. Burnett, M. R. Alvira, J. Marsh, H. C. Ertl, and J. M. Wilson. 2001. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75:11603.
13. Kowalczyk, D. W., A. P. Wlazlo, S. Shane, and H. C. Ertl. 2001. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. Vaccine 19:3583.
14. Cohen, C. J., Z. Q. Xiang, G. P. Gao, H. C. Ertl, J. M. Wilson, and J. M. Bergelson. 2002. Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J. Gen. Virot. 83:151.
15. Doe, B., and C. M. Walker. 1996. HIV-1 p24 Gag-specific cytotoxic T-lymphocyte responses in mice. AIDS 10:793.
16. Ertl, H. C., B. Dietzschold, M. Gore, L. Otvos, Jr., J. K. Larson, W. H. Wunner, and H. Koprowski. 1989. Induction of rabies virus-specific T-helper cells by synthetic peptides that carry dominant T-helper cell epitopes of the viral ribonucleoprotein. J. Virol. 63:2885.
17. Schwartz, S., B. K. Felber, and G. N. Pavlakis. 1992. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J. Virol. 66:150.
18. Schneider, R., M. Campbell, G. Nasioulas, B. K. Felber, and G. N. Pavlakis. 1997. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J. Virol. 71:4892.
19. Qiu, J. T., R. Song, M. Dettenhofer. C. Tian, T. August, B. K. Felber, G. N. Pavlakis, and X. F. Yu. 1999. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J. Virol. 73:9145.
20. Xiang, Z., G. Gao, A. Reyes-Sandoval, C. J. Cohen, Y. Li, J. M. Bergelson, J. M. Wilson, and H. C. Ertl. 2002. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76:2667.
21. Yang, Y., K. U. Jooss, Q. Su. H. C. Ertl, and J. M. Wilson. 1996. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3:137.
22. Zhong, L., A. Granelli-Piperno, Y. Choi, and R. M. Steinman. 1999. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur. J. Immunol. 29:964.
23. Shiver, J. 2001. Merck's HIV vaccine program: research approaches and critical issues. In AIDs Vaccine 2001 Conference, September 5-9. Philadelphia, PA, p. LB5 (Abstr.).
24. Barouch, D. H., A. Craiu, M. J. Kuroda, J. E. Schmitz, X. X. Zheng, S. Santra, J. D. Frost, G. R. Krivulka, M. A. Lifton, C. L. Crabbs, et al. 2000. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA 97:4192.
25. Goepfert, P. A., A. Bansal, B. H. Edwards, G. D. Ritter, Jr., I. Tellez, S. A. McPherson, S. Sabbaj, and M. J. Mulligan. 2000. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce γ interferon. J. Virol. 74:10249.
26. + T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency. J. Virol. 74:4127.
27. + T cells during the chronic phase of infection. J. Virol. 75:2458.